Real World Effectiveness of COVID-19 mRNA Vaccines against Hospitalizations and Deaths in the United States
Vahidy, F. S.; Pischel, L.; Tano, M. E.; Pan, A. P.; Boom, M. L.; Sostman, H. D.; Nasir, K.; Omer, S. B.
Show abstract
The authors have withdrawn this manuscript because they are continuing to review the analytical methods utilized in this iteration of the work and, as of yet, do not have adequate confidence in their reproducibility. Therefore, the authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding author.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A Cost/Benefit Analysis of Clinical Trial Designs for COVID-19 Vaccine Candidates 93%
- Nanograms of SARS-CoV-2 Spike Protein Delivered by Exosomes Induce Potent Neutralization of Both Delta and Omicron Variants. 92%
- Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia 92%
Similar papers in this journal
- Non-clinical safety of GRAd vector-based COVID-19 and HIV vaccines supports a platform regulatory approach 93%
- Safety and efficacy of two immunization schedules with an inactivated SARS-CoV-2 vaccine in adults. A randomized non-inferiority clinical trial 92%
- Self-multimerization of mRNA LNP-derived antigen improves antibody responses 92%
Similar papers in this journal
- An in-depth investigation of the safety and immunogenicity of an inactivated SARS-CoV-2 vaccine 93%
- mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations 93%
- Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern 92%
Similar papers in this journal
- Three-month follow-up of heterologous vs homologous third vaccination in kidney transplant recipients 92%
- Factors associated with the decay of anti-SARS-CoV-2 neutralizing antibodies among recipients of an adenoviral vector-based AZD1222 and a whole-virion inactivated (BBV152) vaccine in Chennai, India: a prospective, longitudinal, cohort study 90%
- Poliovirus Vaccination Induces a Humoral Immune Response that Cross Reacts with SARS-CoV-2 90%
Similar papers in this journal
- Evaluating the neutralizing ability of a CpG-adjuvanted S-2P subunit vaccine against SARS-CoV-2 Variants of Concern 92%
- Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial 91%
- Immunogenicity of a third dose of BNT162b2 to ancestral SARS-CoV-2 & Omicron variant in adults who received two doses of inactivated vaccine 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.